发布求助
文献互助 智能选刊 最新文献

Cardiac Failure Review最新文献

筛选
英文 中文
Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action. 胰高血糖素样肽-1 受体激动剂在多种射血分数保留型心力衰竭病理生理学中的应用：潜在益处和作用机制。
IF 4.2
Cardiac Failure Review Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.15420/cfr.2024.06
Aleksandra Bykova, Maria Serova, Maria Chashkina, Raisa Kosharnaya, Zukhra Salpagarova, Denis Andreev, Ilya Giverts
{"title":"Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action.","authors":"Aleksandra Bykova, Maria Serova, Maria Chashkina, Raisa Kosharnaya, Zukhra Salpagarova, Denis Andreev, Ilya Giverts","doi":"10.15420/cfr.2024.06","DOIUrl":"10.15420/cfr.2024.06","url":null,"abstract":"<p><p>This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction (HFpEF). Traditional heart failure treatment modalities have shown limited success in improving outcomes for patients with HFpEF, but new evidence suggests that GLP-1RAs could be beneficial. The positive effects of GLP-1RAs are likely due to their ability to reduce systemic inflammation, enhance metabolism and directly affect the cardiovascular system, addressing critical aspects of HFpEF pathology. However, the exact impact of GLP-1RAs on clinical outcomes for different HFpEF phenotypes is still unclear. This review highlights both the potential benefits and the current limitations of GLP-1RA therapy, suggesting a careful approach for their application in clinical practice.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"10 ","pages":"e14"},"PeriodicalIF":4.2,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathophysiology of Congestion in Heart Failure: A Contemporary Review. 心力衰竭充血的病理生理学：当代回顾。
IF 4.2
Cardiac Failure Review Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI: 10.15420/cfr.2024.07
Marko Kumric, Tina Ticinovic Kurir, Josko Bozic, Anteo Bradaric Slujo, Duska Glavas, Dino Miric, Mislav Lozo, Jaksa Zanchi, Josip A Borovac
{"title":"Pathophysiology of Congestion in Heart Failure: A Contemporary Review.","authors":"Marko Kumric, Tina Ticinovic Kurir, Josko Bozic, Anteo Bradaric Slujo, Duska Glavas, Dino Miric, Mislav Lozo, Jaksa Zanchi, Josip A Borovac","doi":"10.15420/cfr.2024.07","DOIUrl":"https://doi.org/10.15420/cfr.2024.07","url":null,"abstract":"<p><p>Acutely decompensated heart failure is one of the leading causes of hospitalisation worldwide, with a significant majority of these cases attributed to congestion. Although congestion is commonly mistaken for volume overload, evidence suggests that decompensation can occur without significant water accumulation, being attributed to volume redistribution. Yet, the distinction between intravascular and extravascular congestion in heart failure often blurs, as patients frequently exhibit overlapping features of both, and as patients may transition between phenotypes over time. Considering that differentiation between intravascular and extravascular congestion can lead to different management strategies, the aim of this review was to delineate the pathophysiological nuances between the two, as well as their correlation with clinical, biochemical and imaging indices.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"10 ","pages":"e13"},"PeriodicalIF":4.2,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging Advances in Heart Failure. 心力衰竭的成像进展。
IF 4.2
Cardiac Failure Review Pub Date : 2024-09-16 eCollection Date: 2024-01-01 DOI: 10.15420/cfr.2023.10
Ritu Thamman, Naeimeh Hosseini, Marie-Luise Dikou, Imtiaz U Hassan, Oksana Marchenko, Olukayode Abiola, Julia Grapsa
{"title":"Imaging Advances in Heart Failure.","authors":"Ritu Thamman, Naeimeh Hosseini, Marie-Luise Dikou, Imtiaz U Hassan, Oksana Marchenko, Olukayode Abiola, Julia Grapsa","doi":"10.15420/cfr.2023.10","DOIUrl":"10.15420/cfr.2023.10","url":null,"abstract":"<p><p>This paper delves into the significance of imaging in the diagnosis, aetiology and therapeutic guidance of heart failure, aiming to facilitate early referral and improve patient outcomes. Imaging plays a crucial role not only in assessing left ventricular ejection fraction, but also in characterising the underlying cardiac abnormalities and reaching a specific diagnosis. By providing valuable data on cardiac structure, function and haemodynamics, imaging helps diagnose the condition, evaluate haemodynamic status and, consequently, identify the underlying pathophysiological phenotype, as well as stratifying the risk for outcomes. In this article, we provide a comprehensive exploration of these aspects.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"10 ","pages":"e12"},"PeriodicalIF":4.2,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcatheter Aortic Valve Replacement is Ready for Most Low-risk Patients: A Systematic Review of the Literature. 大多数低风险患者可以接受经导管主动脉瓣置换术：文献的系统回顾。
IF 4.2
Cardiac Failure Review Pub Date : 2024-09-13 eCollection Date: 2024-01-01 DOI: 10.15420/cfr.2023.23
Ahmad Jabri, Anas Alameh, Gennaro Giustino, Pedro Engel Gonzalez, Brian O'Neill, Rodrigo Bagur, Pedro Cox, Tiberio Frisoli, James Lee, Dee Dee Wang, William W O'Neill, Pedro Villablanca
{"title":"Transcatheter Aortic Valve Replacement is Ready for Most Low-risk Patients: A Systematic Review of the Literature.","authors":"Ahmad Jabri, Anas Alameh, Gennaro Giustino, Pedro Engel Gonzalez, Brian O'Neill, Rodrigo Bagur, Pedro Cox, Tiberio Frisoli, James Lee, Dee Dee Wang, William W O'Neill, Pedro Villablanca","doi":"10.15420/cfr.2023.23","DOIUrl":"10.15420/cfr.2023.23","url":null,"abstract":"<p><p>Transcatheter aortic valve replacement (TAVR) has undergone rapid expansion, emerging as a viable therapeutic option for low-risk patients in lieu of surgical aortic valve replacement. This paper aims to provide a review of the scientific evidence concerning TAVR in low-risk patients, encompassing both observational and clinical trial data. Furthermore, a substantial proportion of low-risk patients possesses a bicuspid aortic valve, necessitating careful examination of the pertinent anatomic and clinical considerations to TAVR that is highlighted in this review. Additionally, the review expands upon some of the unique challenges associated with alternate access in low-risk patients evaluated for TAVR. Last, this review outlines the pivotal role of a multidisciplinary heart team approach in the execution of all TAVR procedures and the authors' vision of 'minimalist TAVR' as a new era in low-risk TAVR.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"10 ","pages":"e11"},"PeriodicalIF":4.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life. 胰高血糖素样肽-1 受体激动剂对心功能、运动能力和生活质量的影响
IF 4.2
Cardiac Failure Review Pub Date : 2024-09-11 eCollection Date: 2024-01-01 DOI: 10.15420/cfr.2024.05
Anastasia Shchendrygina, Amina Rakisheva, Ilya Giverts, Yasmin Rustamova, Anzhela Soloveva
{"title":"Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life.","authors":"Anastasia Shchendrygina, Amina Rakisheva, Ilya Giverts, Yasmin Rustamova, Anzhela Soloveva","doi":"10.15420/cfr.2024.05","DOIUrl":"10.15420/cfr.2024.05","url":null,"abstract":"<p><p>Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering agents primarily used in managing diabetes and obesity. Recently, GLP-1 RAs have garnered attention for their cardiovascular benefits beyond glycaemic control in patients with type 2 diabetes, exhibiting patterns previously seen in cardiovascular outcomes trials on sodium-glucose cotransporter 2 inhibitors, which now receive a high level of recommendation for the treatment of heart failure (HF). GLP-1 RAs have been increasingly investigated in HF cohorts, but mainly in small-scale studies reporting inconclusive findings regarding clinical outcomes and different safety profiles in HF patients with reduced and preserved ejection fractions. This review discusses the effects of GLP-1 RAs on surrogate HF outcomes, such as cardiac structure and function, exercise capacity and quality of life, in HF patients across the spectrum of left ventricular ejection fraction, to provide insights into the potential of these agents to be investigated in large clinical trials to evaluate clinical outcomes.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"10 ","pages":"e10"},"PeriodicalIF":4.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Haemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients. 钠葡萄糖转运体 2 抑制剂对慢性心力衰竭患者血流动力学的影响
IF 4.2
Cardiac Failure Review Pub Date : 2024-09-11 eCollection Date: 2024-01-01 DOI: 10.15420/cfr.2023.25
C Noah Nilsson, Mads Kristian Ersbøll, Finn Gustafsson
{"title":"Haemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients.","authors":"C Noah Nilsson, Mads Kristian Ersbøll, Finn Gustafsson","doi":"10.15420/cfr.2023.25","DOIUrl":"10.15420/cfr.2023.25","url":null,"abstract":"<p><p>Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are now recommended in the current European Society of Cardiology/American College of Cardiology guidelines for the treatment of heart failure (HF) across the spectrum of left ventricular ejection fraction (LVEF) and several large trials have documented the beneficial effects of this drug class on cardiovascular outcomes. Although the clinical efficacy of SGLT-2 inhibition in HF is now well recognised, research is still ongoing to better understand the underlying mechanistic effects of this drug class. In this paper we assess the haemodynamic effects following SGLT-2i treatment in HF patients by reviewing the current literature. We focus our review on preload of the LV in terms of filling pressure and pulmonary artery pressure, cardiac output and afterload. We discuss these variables stratified according to HF with reduced LVEF (HFrEF) and HF with preserved LVEF (HFpEF). Finally, we examine the evidence of LV remodelling in the setting of SGLT-2i-related changes in haemodynamics.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"10 ","pages":"e09"},"PeriodicalIF":4.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction. 保留射血分数心力衰竭的流行病学、临床特征和病因特异性结局。
Cardiac Failure Review Pub Date : 2023-11-17 eCollection Date: 2023-01-01 DOI: 10.15420/cfr.2023.03
Chris J Kapelios, Bahira Shahim, Lars H Lund, Gianluigi Savarese
{"title":"Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction.","authors":"Chris J Kapelios, Bahira Shahim, Lars H Lund, Gianluigi Savarese","doi":"10.15420/cfr.2023.03","DOIUrl":"https://doi.org/10.15420/cfr.2023.03","url":null,"abstract":"<p><p>Heart failure (HF) is a global pandemic affecting 64 million people worldwide. HF with preserved ejection fraction (HFpEF) has traditionally received less attention than its main counterpart, HF with reduced ejection fraction (HFrEF). The incidence and prevalence of HFpEF show geographic variation and are increasing over time, soon expected to surpass those of HFrEF. Morbidity and mortality rates of HFpEF are considerable, albeit lower than those of HFrEF. This review focuses on the burden of HFpEF, providing contemporary data on epidemiology, clinical characteristics and comorbidities, cause-specific outcomes, costs and pharmacotherapy.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"9 ","pages":"e14"},"PeriodicalIF":0.0,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers to Improve Decision-making in Acute Heart Failure. 改善急性心力衰竭决策的生物标志物。
Cardiac Failure Review Pub Date : 2023-10-25 eCollection Date: 2023-01-01 DOI: 10.15420/cfr.2023.08
Rafael de la Espriella, Gonzalo Núñez-Marín, Pau Codina, Julio Núñez, Antoni Bayés-Genís
{"title":"Biomarkers to Improve Decision-making in Acute Heart Failure.","authors":"Rafael de la Espriella, Gonzalo Núñez-Marín, Pau Codina, Julio Núñez, Antoni Bayés-Genís","doi":"10.15420/cfr.2023.08","DOIUrl":"10.15420/cfr.2023.08","url":null,"abstract":"<p><p>Acute heart failure (AHF) is a complex clinical syndrome that requires prompt diagnosis, risk stratification and effective treatment strategies to reduce morbidity and mortality. Biomarkers are playing an increasingly important role in this process, offering valuable insights into the underlying pathophysiology and facilitating personalised patient management. This review summarises the significance of various biomarkers in the context of AHF, with a focus on their clinical applications to stratify risk and potential for guiding therapy choices.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"9 ","pages":"e13"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71522819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction. 保留射血分数的心力衰竭中神经激素调节的病理生理学原理和临床证据。
IF 4.2
Cardiac Failure Review Pub Date : 2023-06-05 eCollection Date: 2023-01-01 DOI: 10.15420/cfr.2022.23
Vincenzo Castiglione, Francesco Gentile, Nicolò Ghionzoli, Martina Chiriacò, Giorgia Panichella, Alberto Aimo, Giuseppe Vergaro, Alberto Giannoni, Claudio Passino, Michele Emdin
{"title":"Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction.","authors":"Vincenzo Castiglione, Francesco Gentile, Nicolò Ghionzoli, Martina Chiriacò, Giorgia Panichella, Alberto Aimo, Giuseppe Vergaro, Alberto Giannoni, Claudio Passino, Michele Emdin","doi":"10.15420/cfr.2022.23","DOIUrl":"10.15420/cfr.2022.23","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome resulting from the interaction between cardiac diseases, comorbidities and ageing. HFpEF is characterised by the activation of neurohormonal axes, namely of the renin-angiotensin-aldosterone system and the sympathetic nervous system, although to a lesser extent compared with heart failure with reduced ejection fraction. This provides a rationale for neurohormonal modulation as a therapeutic approach for HFpEF. Nonetheless, randomised clinical trials have failed to demonstrate a prognostic benefit from neurohormonal modulation therapies in HFpEF, with the sole exception of patients with left ventricular ejection fraction in the lower range of normality, for whom the American guidelines suggest that such therapies may be considered. In this review, the pathophysiological rationale for neurohormonal modulation in HFpEF is summarised and the clinical evidence on pharmacological and nonpharmacological approaches backing current recommendations discussed.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"9 ","pages":"e09"},"PeriodicalIF":4.2,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/13/cfr-09-e09.PMC10326668.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9814663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging in Heart Failure with Preserved Ejection Fraction: A Multimodality Imaging Point of View. 保留射血分数的心力衰竭的成像：多模态成像视角。
IF 4.2
Cardiac Failure Review Pub Date : 2023-04-04 eCollection Date: 2023-01-01 DOI: 10.15420/cfr.2022.27
Serkan Ünlü, Özge Özden, Ahmet Çelik
{"title":"Imaging in Heart Failure with Preserved Ejection Fraction: A Multimodality Imaging Point of View.","authors":"Serkan Ünlü, Özge Özden, Ahmet Çelik","doi":"10.15420/cfr.2022.27","DOIUrl":"10.15420/cfr.2022.27","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) is an important global health problem. Despite increased prevalence due to improved diagnostic options, limited improvement has been achieved in cardiac outcomes. HFpEF is an extremely complex syndrome and multimodality imaging is important for diagnosis, identifying its different phenotypes and determining prognosis. Evaluation of left ventricular filling pressures using echocardiographic diastolic function parameters is the first step of imaging in clinical practice. The role of echocardiography is becoming more popular and with the recent developments in deformation imaging, cardiac MRI is extremely important as it can provide tissue characterisation, identify fibrosis and optimal volume measurements of cardiac chambers. Nuclear imaging methods can also be used in the diagnosis of specific diseases, such as cardiac amyloidosis.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"9 ","pages":"e04"},"PeriodicalIF":4.2,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/45/cfr-09-e04.PMC10301698.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信